Centessa Pharmaceuticals (NASDAQ:CNTA) Price Target Lowered to $4.00 at Morgan Stanley

Centessa Pharmaceuticals (NASDAQ:CNTAGet Rating) had its price objective trimmed by Morgan Stanley from $5.00 to $4.00 in a research note issued to investors on Tuesday morning, Benzinga reports. The brokerage currently has an underweight rating on the stock.

Centessa Pharmaceuticals Price Performance

Shares of NASDAQ:CNTA opened at $3.87 on Tuesday. The company has a 50-day simple moving average of $3.59 and a 200-day simple moving average of $4.03. Centessa Pharmaceuticals has a one year low of $2.88 and a one year high of $11.19. The company has a debt-to-equity ratio of 0.18, a quick ratio of 12.49 and a current ratio of 12.49. The stock has a market capitalization of $366.09 million, a price-to-earnings ratio of -1.52 and a beta of 0.40.

Centessa Pharmaceuticals (NASDAQ:CNTAGet Rating) last issued its quarterly earnings results on Thursday, November 10th. The company reported ($0.57) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.49) by ($0.08). On average, analysts predict that Centessa Pharmaceuticals will post -2.22 EPS for the current year.

Insider Transactions at Centessa Pharmaceuticals

In other news, EVP Antoine Yver sold 9,700 shares of the business’s stock in a transaction dated Tuesday, November 1st. The shares were sold at an average price of $4.03, for a total transaction of $39,091.00. Following the transaction, the executive vice president now directly owns 765,059 shares in the company, valued at $3,083,187.77. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Insiders have sold a total of 26,070 shares of company stock worth $98,010 over the last ninety days. 9.09% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Prelude Capital Management LLC acquired a new position in Centessa Pharmaceuticals during the first quarter worth about $102,000. Golden State Equity Partners grew its position in Centessa Pharmaceuticals by 15.1% during the first quarter. Golden State Equity Partners now owns 15,970 shares of the company’s stock worth $143,000 after buying an additional 2,100 shares during the period. Goldman Sachs Group Inc. acquired a new position in Centessa Pharmaceuticals during the second quarter worth about $81,000. Jane Street Group LLC acquired a new position in Centessa Pharmaceuticals during the second quarter worth about $192,000. Finally, Alps Advisors Inc. acquired a new position in Centessa Pharmaceuticals during the second quarter worth about $272,000. 78.03% of the stock is currently owned by institutional investors and hedge funds.

Centessa Pharmaceuticals Company Profile

(Get Rating)

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines to patients. Its registrational pipeline products include Lixivaptan, a vasopressin V2 receptor small molecule inhibitor that is in Phase III clinical development for the treatment of autosomal dominant polycystic kidney disease; and SerpinPC, an activated protein C inhibitor, which is in Phase IIa clinical development for the treatment of hemophilia A and B.

See Also

Receive News & Ratings for Centessa Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Centessa Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.